FDA Approves Zanvastro, First Disease-Modifying Therapy for Alexander Disease
核心洞察
The FDA has approved Ionis Pharmaceuticals' Zanvastro (搜索) (zilganersen), the first disease-modifying treatment for Alexander disease (搜索), an ultra-rare and often fatal neurological disorder.
Approval was based on a global randomized, double-blind, placebo-controlled Phase 1-3 study in which the 50 mg dose stabilized gait speed in patients aged five and older.
Zanvastro (搜索) is given as a 50 mg intrathecal injection every three months and will launch at $285,000 per dose, an implied annual list cost of roughly $1.14 million.
The FDA has approved Zanvastro (搜索) (zilganersen), an antisense oligonucleotide from Ionis Pharmaceuticals, for pediatric and adult patients with Alexander disease (搜索), making it the first approved disease-modifying treatment for the ultra-rare, progressive and often fatal neurological disorder. The approval marks Ionis' first independently launched neurology medicine and the culmination of more than a decade of research into the disease's biology.
Alexander disease (搜索) damages the nervous system and can impair movement, speech, swallowing, and cognitive function, as well as motor, cognitive, autonomic and gastrointestinal function. It affects fewer than 1,000 people in the United States according to National Institutes of Health data cited by Reuters, while Ionis' press release cites a figure of about 300 people in the U.S. Before the approval, treatment was mostly limited to managing symptoms.
"There's tremendous excitement about the fact that we now have a disease-modifying therapy for Alexander disease (搜索), that Zanvastro (搜索) gets to the underlying biology," said Amy Waldman, MD, pediatric neurologist at the Children's Hospital of Philadelphia, who led the clinical program. She noted that research into the disease's underlying biology, manifestations and trajectories dates back to around the 1980s, with a natural history study beginning in 2016.
Mechanism and Dosing
As an antisense oligonucleotide, Zanvastro (搜索) works by reducing glial fibrillary acidic protein (搜索) (GFAP), the toxic accumulation of astrocytes in the brain that leads to the formation of Rosenthal fibers that disrupt neurological function. The drug is approved as a 50 mg dose administered quarterly as an intrathecal injection.
Trial Results
The FDA based its decision on a global, randomized, double-blind, placebo-controlled Phase 1–3 study involving 53 people with Alexander disease (搜索) aged 2 to 53 years, who were randomly assigned 2:1 to 25 mg Zanvastro (搜索), 50 mg Zanvastro, or control. A separate report of the study describes 54 participants between 1.5 and 53 years old.
In participants aged 5 years and older, Zanvastro (搜索) produced significant stabilization of gait speed on the 10-Meter Walk Test compared with controls after 60 weeks. At baseline, the 50 mg group (n = 17) had a mean gait speed of 1.2 meters/second versus 1.1 m/s in the control group (n = 13). After 61 weeks, the Zanvastro group showed a least-squares mean percent change of –2.1% (95% CI, –23 to 18.8), compared with –35.4% for controls (95% CI, –59.3 to –11.5), a least-squares mean difference of 33.3% (95% CI, 1.4–65.3; p = 0.041).
"It was very humbling that in those just 15 months ... there was a decline in patients who were relatively stable to begin with," Waldman said. "The fact that patients continued to worsen in the control arm compared to the stability that was seen in Zanvastro (搜索) was quite an achievement."
Researchers also observed significant differences in change from baseline in plasma GFAP levels at week 61, which Waldman said showed evidence of modulation of the underlying cause of disease (LSM difference 33.6%, P = .003). For participants aged 2 to 4 years, the study showed significant differences on the Gross Motor Function Measure-88 at week 61 (LSM difference 22.9%, P = .034). An open-label study of four patients younger than 2 years was also conducted.
"It's a very heterogeneous disease, and we were very fortunate that this trial was for all ages, all disease phenotypes, so we could offer it to everyone," Waldman said. "Even with such heterogeneity, that it met its statistical endpoints and had clinical meaningful benefits is really tremendous."
Safety Profile
Most adverse reactions were mild or moderate, with the most common including vomiting, back pain, cough, headache and post-lumbar puncture syndrome. One case of aseptic meningitis occurred, but the patient was able to continue therapy and was re-dosed successfully. "The drug was very well tolerated," Waldman said. "There weren't really any of those significant things that didn't resolve with just some supportive care."
Commercial and Access Considerations
Ionis has set a price of $285,000 per dose and expects Zanvastro (搜索) to generate more than $100 million in peak annual sales. Because the drug is administered once every three months, a full year of treatment implies four doses and approximately $1.14 million in annual list-price cost before discounts, insurance coverage, or patient assistance. The company said financial assistance and reimbursement support programs are in place to help patients start and stay on treatment.
The ultra-rare patient population means Ionis does not need thousands of patients to reach its peak-sales forecast, but finding eligible patients, securing reimbursement, and coordinating treatment through specialist centers could make adoption gradual. Ionis expects the drug to become available in the United States in the coming weeks but has not disclosed launch-year sales guidance. The company said it will work to bring Zanvastro (搜索) to 12 leukodystrophy centers of excellence in the U.S. to ensure identified patients can gain access, while also reaching neurologists outside that network to identify new patients.
Oppenheimer analyst Jay Olson believes the approval meaningfully reduces perceived risk around Ionis' wider neurology pipeline, including obudanersen (搜索) for Angelman syndrome (搜索), for which late-stage results are expected in the second half of 2027.
Beyond Alexander disease (搜索), Waldman said Zanvastro (搜索)'s results offer proof of concept for other diseases involving gain of function, loss of function and other leukodystrophies. "I think people are so focused right now on gene therapy or CRISPR-Cas9 or other things, and it's just a reminder that we really do have a number of tools that can work for these incurable neurologic conditions," she said.